Janine Schuurman

USPTO Granted Patents = 53 (Patent Applications = 68)

CIPO Patents = 2 (Patent Applications = 4)

EPO Patents = 30 (Patent Applications = 40)

Average Co-Inventor Count = 7.0

ph-index = 13

Forward Citations = 555(Granted Patents)

Forward Citations (Not Self Cited) = 457(Oct 12, 2025)

Location History:

Amsterdam, NL (2006 - 2015)
Ultrecht, NL (2017)
Utrecht, NL (2015 - 2024)
Diemen, NL (2015 - 2024)

Company Filing History:

Janssen Biotech, Inc.

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12398214 - Binding agents binding to EpCAM and CD137 (2025-08-26),

2. 12338289 - Antibody variant combinations and uses thereof (2025-06-24),

3. 12247080 - Anti-DR5 antibodies and methods of use thereof (2025-03-11),

4. 12247077 - Bispecific EGFR/c-Met antibodies (2025-03-11),

5. 12247065 - Method for producing a controlled mixture of two or more different antibodies (2025-03-11),

6. 12173076 - Polypeptide variants and uses thereof (2024-12-24),

7. 12049512 - Antibody variants and uses thereof (2024-07-30),

8. 11932693 - Monoclonal antibodies directed against programmed death-1 protein and their use in medicine (2024-03-19),

9. 11866514 - Heterodimeric antibody Fc-containing proteins and methods for production thereof (2024-01-09),

10. 11613575 - Humanized or chimeric CD3 antibodies (2023-03-28),

11. 11578141 - Bispecific antibodies against HER2 and CD3 (2023-02-14),

12. 11512140 - Monoclonal antibodies against c-Met (2022-11-29),

13. 11492371 - Production of heterodimeric proteins (2022-11-08),

14. 11485796 - Inert format (2022-11-01),

15. 11359015 - Humanized or chimeric CD3 antibodies (2022-06-14),

Title: Innovator Spotlight: Janine Schuurman

Introduction:

Janine Schuurman, a prolific inventor hailing from Diemen, Netherlands, has left an indelible mark in the field of medicine with his groundbreaking innovations and numerous patents.

Latest Patents:

Among his impressive portfolio of 46 patents, one of his latest inventions includes "Monoclonal antibodies directed against programmed death-1 protein and their use in medicine." This patent revolves around antibodies capable of binding to the immune checkpoint protein programmed death-1 (PD-1). These modified antibodies exhibit reduced Fc-mediated effector function, making them valuable in the realm of immunotherapy, particularly in cancer treatment.

Career Highlights:

Schuurman has made significant contributions to renowned companies like Genmab A/S and Janssen Biotech, Inc., where his innovative spirit thrived. His expertise in developing novel heterodimeric antibody-Fc-containing proteins, including bispecific antibodies, has garnered acclaim in the industry.

Collaborations:

Throughout his career, Schuurman has collaborated closely with esteemed professionals such as Paul Parren and Aran Frank Labrijn. Together, they have pushed the boundaries of medical research and paved the way for cutting-edge advancements in antibody technologies.

Conclusion:

In conclusion, Janine Schuurman stands as a trailblazing inventor who continues to revolutionize the field of medicine with his patent-worthy innovations. His relentless pursuit of excellence and collaborative efforts underscore his invaluable contributions to the scientific community.

This text is generated by artificial intelligence and may not be accurate.